Nautilus Biotechnology, Inc. (NAUT) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a proteomics platform (the "Nautilus platform") to quantify and analyze the proteome. The company has not yet commercialized any products and has not generated any revenue since inception. It operates as a single reporting segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(13.6) million | $(16.4) million | $(45.2) million | $(53.2) million |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.13) | $(0.36) | $(0.42) |
| Operating Expenses | $15.5 million | $19.1 million | $51.4 million | $61.5 million |
| Research & Development (R&D) | $9.6 million | $12.3 million | $31.5 million | $37.7 million |
| General & Administrative (G&A) | $5.9 million | $6.8 million | $19.9 million | $23.8 million |
| Interest Income | $1.9 million | $2.7 million | $6.2 million | $8.3 million |
| Cash, Cash Equivalents & Investments | $168.5 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $318.2 million (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities (YTD) | $(38.3) million | $(44.8) million |
Material Changes vs. Prior Period
- Expense Reductions: Total operating expenses decreased by 19% in Q3 2025 and 16% YTD 2025 compared to the prior year periods. This was driven by a workforce reduction implemented in Q1 2025, resulting in lower salaries and benefits, as well as reduced stock-based compensation expense as merger-era options were fully expensed.
- Interest Income Decline: Interest income decreased due to lower cash and investment balances and decreased yield rates on investments.
- Investment Portfolio: The company held $168.5 million in cash, cash equivalents, and investments as of September 30, 2025. This includes $23.9 million in cash and cash equivalents, $107.6 million in short-term investments, and $37.1 million in long-term investments.
- Legal Resolution: A declaratory judgment suit filed against Somalogic (now Standard Biotools) and the California Institute of Technology regarding DNA origami structures was dismissed and settled in November 2024.
Guidance, Outlook, and Risks
- Commercialization Timeline: The company is currently in the collaboration phase. It plans to launch an "early access" limited release in the first half of 2026, starting with targeted service offerings for the analysis of the Tau protein (associated with Alzheimer's disease). A broader commercial launch is anticipated in late 2026.
- Liquidity: Management believes existing cash resources are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund development and commercialization.
- Nasdaq Listing Status: The company received a deficiency notice in May 2025 for failing to maintain the $1.00 minimum bid price requirement on the Nasdaq Global Select Market. On October 27, 2025, Nasdaq approved the transfer of the company's listing to the Nasdaq Capital Market, effective October 29, 2025. This grants an additional 180-day compliance period (until April 26, 2026) to regain the $1.00 bid price. The company intends to effect a reverse stock split if necessary to regain compliance.
- Key Risks:
- Dependence on the successful development and commercialization of the unproven Nautilus platform.
- Need for additional financing; failure to raise capital could force delays or termination of operations.
- Supply chain disruptions and reliance on single-source suppliers for critical components.
- Regulatory uncertainty regarding FDA classification of products if they are used for clinical diagnostics.
- Intellectual property litigation risks and the need to defend patent rights.
Investor Verification Checklist
- Verify the company's ability to raise additional capital given the $318.2 million accumulated deficit and lack of revenue.
- Monitor the stock price to ensure compliance with the Nasdaq Capital Market minimum bid price requirement by April 26, 2026, and watch for announcements regarding a potential reverse stock split.
- Assess the progress of the "early access" launch scheduled for H1 2026 and the validation of the Tau protein assay.
- Review the status of supply chain dependencies, particularly for single-source components and reagents.
- Track the impact of the Q1 2025 workforce reduction on the company's ability to execute its development and commercialization plans.